Who are XL184's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Letybo®, Sunitinib Malate (SU011248), pazopanib or guideline conform chemotherapy, Lenvatinib + losartan, Sunitinib (Sutent), Anlotinib hydrochloride capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xl184.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

XL184 — Competitive Intelligence Brief

XL184 (XL184) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-targeted tyrosine kinase inhibitor. Area: Oncology.

phase 3 Multi-targeted tyrosine kinase inhibitor MET, VEGFR2, RET Oncology Small molecule Live · refreshed every 30 min

Target snapshot

XL184 (XL184) — Exelixis. XL184 is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and RET signaling to inhibit tumor growth and angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
XL184 TARGET	XL184	Exelixis	phase 3	Multi-targeted tyrosine kinase inhibitor	MET, VEGFR2, RET
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2
Sunitinib Malate (SU011248)	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Sunitinib (Sutent)	Sunitinib (Sutent)	Sponsor GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Anlotinib hydrochloride capsules	Anlotinib hydrochloride capsules	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, FGFR, PDGFR, c-Kit, RET

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-targeted tyrosine kinase inhibitor class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Exelixis · 2 drugs in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Cancer Institute, Naples · 1 drug in this class
Sponsor GmbH · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
TransThera Sciences (Nanjing), Inc. · 1 drug in this class
Advenchen Laboratories Nanjing Ltd. · 1 drug in this class
University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). XL184 — Competitive Intelligence Brief. https://druglandscape.com/ci/xl184. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab